ALKS - Alkermes plc
Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 95.2% of Alkermes shares are
The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct equity holdings.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $40.30 and traded as high as $49.35. Alkermes shares last traded at $49.16, with a volume of 660,776 shares. Wall Street Analysts Forecast Growth Several brokerages have
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,.
Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,210,851 shares of the company's stock after selling 122,254 shares during the quarter. Bank
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 378,090 shares of the company's stock after selling 34,830 shares during the period. Glenmede Trust Co. NA owned about
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alkermes NASDAQ: ALKS reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company's acquisition of Avadel. The company also highlighted progress across its orexin development pipeline and reiterated most of its full-year financial outlook.
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today, to discuss these financial results and expectations, and provide an update on the company. The webcast ma.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast.
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced results from a planned interim analysis of the ongoing long-term extension (LTE) study evaluating alixorexton in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Across all dose groups in both NT1 and NT2 participants, alixorexton demonstrated sustained clinically meaningful improvement from baseline1 on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week 24 of the LTE, approxim.
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
On June 23, 2026, Alkermes PLC (ALKS) shares rose 4.3% today, bringing the current price to $48.06. Over the past week, shares increased by 9.0%, and have seen
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.